Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Company Overview - Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is advancing its lead candidate fasedienol for the treatment of Social Anxiety Disorder (SAD) [2] Product Development - The progress of fasedienol is based on the company's ongoing research and development efforts aimed at addressing the needs of patients with SAD [2]